BAMS
ALXN

Bellevue Asset Management (Switzerland)’s Alexion Pharmaceuticals ALXN Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$9.42M Hold
49,400
– – 1.44% 19
2015
Q3 		$7.73M Sell
49,400
-2,346
-5% -$428K 1.26% 23
2015
Q2 		$9.35M Sell
51,746
-21,000
-29% -$3.62M 1.3% 24
2015
Q1 		$12.6M Buy
+72,746
New +$13.2M 1.76% 12

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s ALXN Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) held its Alexion Pharmaceuticals (ALXN) position steady in Q4 2015 at 49,400 shares worth $9.42M. The position accounts for 1.44% of the portfolio, ranked #19.

Bellevue Asset Management (Switzerland) first reported a position in ALXN in Q1 2015 and has held it in 4 quarters since. The position peaked at $12.6M in Q1 2015. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 49,400 shares of Alexion Pharmaceuticals worth $9.42M as of Q4 2015.
  • Bellevue Asset Management (Switzerland) left its Alexion Pharmaceuticals share count unchanged in Q4 2015.
  • Alexion Pharmaceuticals made up 1.44% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #19 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Alexion Pharmaceuticals in Q1 2015 and has held it in 4 quarters since.
  • Bellevue Asset Management (Switzerland)'s Alexion Pharmaceuticals position peaked at $12.6M in Q1 2015.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.